BCM
JANX icon

BML Capital Management’s Janux Therapeutics JANX Stock Holding History

BML Capital Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.61M Sell
151,126
-3,835
-2% -$64.4K 1.39% 14
2026
Q2 		$2.38M Hold
154,961
– – 1.35% 12
2026
Q1 		$2.15M Buy
+154,961
New +$2.12M 1.38% 12

Other funds holding JANX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

BML Capital Management's JANX Position: Q3 2026 in Review

BML Capital Management reduced its Janux Therapeutics (JANX) stake by 2.5% in Q3 2026, selling an estimated $64.4K and leaving 151,126 shares worth $2.61M. The position accounts for 1.39% of the portfolio, ranked #14.

BML Capital Management first reported a position in JANX in Q1 2026 and has held it in 3 quarters since. 94 funds tracked by Wall St. Rank hold JANX as of Q3 2026.

  • BML Capital Management held 151,126 shares of Janux Therapeutics worth $2.61M as of Q3 2026.
  • BML Capital Management sold 3,835 Janux Therapeutics shares in Q3 2026, an estimated $64.4K.
  • Janux Therapeutics made up 1.39% of BML Capital Management's portfolio in Q3 2026, its #14 holding.
  • BML Capital Management first reported a position in Janux Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 94 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2026.

Based on BML Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.